Tumor News and Research

RSS

Experimental drug inhibits BTK molecule in patients with chronic lymphocytic leukemia

A new study led by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James) helps confirm that a molecule targeted by the experimental drug ibrutinib is critical for the development of chronic lymphocytic leukemia, the most common form of adult leukemia.

20 Dec 2013

Joint initiative aims to eradicate health disparities among communities of color in the U.S.

The world's first and largest group medical practice and one of the nation's premier volunteer service organizations of professional African American women are joining forces to eradicate health disparities among communities of color in the United States. Mayo Clinic and The Links, Incorporated have established a formal collaboration that aims to develop a more diverse health care workforce.

20 Dec 2013

Study finds milk serves as protective carrier of bioactive molecules

Polyphenols found in tea manifest anti-cancer effects but their use is limited by poor bioavailability and disagreeable taste. A new study in the Journal of Dairy Science- finds that when epigallocatechin gallate (EGCG), the major extractable polyphenol in green tea and the most biologically active, when diluted in skim milk or other milk complexes remains bioactive and continues to reduce colon cancer cell proliferation in culture at concentrations higher than 0.03 mg of EGCG/mL.

20 Dec 2013

Researchers identify molecular link between liver cancer, obesity, alcoholism, and hepatitis

Obesity, alcoholism, and chronic hepatitis all increase the risk of getting liver cancer, which is the third leading cause of cancer death worldwide. Obesity in particular is driving a significant increase in liver cancer in the United States.

20 Dec 2013

New research assesses nanomedicine-based approaches for treating cancer

As cancer maintains its standing as the second leading cause of death in the U.S., researchers have continued their quest for safer and more effective treatments. Among the most promising advances has been the rise of nanomedicine, the application of tiny materials and devices whose sizes are measured in the billionths of a meter to detect, diagnose and treat disease.

20 Dec 2013

Immunologists discover risk factor responsible for infectious mononucleosis in young people

More than 90 percent of all adults are carriers of the oncogenic Epstein-Barr Virus. Primary infection with this herpes virus as a young child is generally not linked to any symptoms, and usually offers life-long protection from its cancer-causing effect. However, for people who do not become infected with the virus until adolescence, the infection often leads to infectious mononucleosis (commonly known as glandular fever). Our immune systems can generally fend off this disease after a period of between one and several months. However, there is an increased risk of developing Hodgkin lymphoma at a later stage, a cancerous tumor of the lymphatic system.

20 Dec 2013

Takeda to acquire exclusive license to develop Natrogen's Natura-alpha compound

Takeda Pharmaceutical Company Limited and Natrogen Therapeutics International, Inc. jointly announced today an agreement whereby Takeda will acquire an exclusive license to develop Natrogen's Natura-alpha compound as well as an option to acquire Natrogen. Natura-alpha is a synthetic small molecule oral compound that is believed to inhibit pro-inflammatory cytokine expression, which may help to reduce gastrointestinal inflammation. Natura-alpha is currently in Phase 2 development for the treatment of ulcerative colitis.

20 Dec 2013

BeiGene doses first patient in Phase 1 study of BGB-283

BeiGene (Beijing), Co., Ltd., today announced dose administration for the first patient in a Phase 1 study of BGB-283 in patients with B-RAF or K-RAS mutations. BGB-283 is an investigational, oral, selective, potent second generation inhibitor of B-RAF, making it a targeted therapeutic candidate to potentially treat and bring benefit to patients with cancers that harbor BRAF mutations and/or aberrations in the RAS-MAPK (mitogen-activated protein kinase) pathway.

20 Dec 2013

Researchers receive Doris Duke Foundation award to predict sickle cell crisis, monitor treatments

Researchers at Case Western Reserve University have received a $486,000 Doris Duke Foundation award to discover how to predict when sickle cell disease patients will suffer an acute crisis and monitor the effectiveness of treatments.

20 Dec 2013

Blaze Bioscience to initiate first Phase 1 clinical study of BLZ-100 in patients with skin tumors

Blaze Bioscience, Inc. and its subsidiary, Blaze Bioscience Australia Pty Ltd, today announced the initiation of the first Phase 1 clinical study of the first Tumor Paint product candidate, BLZ-100. The study, titled "A Phase I Dose Escalation/Expansion Study of BLZ-100 Administered by Intravenous Injection in Adult Subjects with Skin Cancer," will enroll up to 30 patients with basal cell carcinoma, squamous cell carcinoma, or amelanotic melanoma.

19 Dec 2013

Abramson Cancer Center of the University of Pennsylvania celebrates 40th anniversary

This December marks the 40th anniversary of the Abramson Cancer Center of the University of Pennsylvania being designated a Comprehensive Cancer Center by the National Cancer Institute. To celebrate this momentous milestone, over 400 people gathered together early this month for an event recognizing the center's vast achievements in cancer research, patient care, and education during the last four decades.

19 Dec 2013

LSDF announces research and development grants to commercialize health-related technologies

The Life Sciences Discovery Fund (LSDF) today announced $1.1 million in five Proof of Concept grants to Washington for-profit and non-profit organizations to foster the translation of health-related products from the laboratory into the commercial marketplace.

19 Dec 2013

TGen, Nemucore, and Barrow collaboration aims for new drugs to treat glioblastoma

The Ben & Catherine Ivy Foundation today announced a $3 million grant to the Translational Genomics Research Institute (TGen), Nemucore Medical Innovations Inc., and Barrow Neurological Institute at St. Joseph's Hospital and Medical Center to help fund significant brain tumor research in Arizona.

18 Dec 2013

Researchers receive Special Challenge Award to investigate role of high protein levels in prostate tumors

Cleveland Clinic, along with the National Cancer Institute, the University of Chicago and Thomas Jefferson University, are the recipients of a $600,000 Special Challenge Award from the Prostate Cancer Foundation (PCF) to investigate the role of abnormally high protein levels in prostate tumors.

18 Dec 2013

Aerobic glycolysis is a cause of malignancy, show Berkeley Lab researchers

Metabolism was lost in the shadows of cancer research for decades but has recently been reclaiming some of the spotlight. Now, Mina Bissell, Distinguished Scientist with Berkeley Lab's Life Sciences Division and a leading authority on breast cancer, has shown that aerobic glycolysis - glucose metabolism in the presence of oxygen - is not the consequence of the cancerous activity of malignant cells but is itself a cancerous event.

18 Dec 2013

Merck signs license agreement with CNIO for cancer drug development

Merck Serono, the biopharmaceutical division of Merck, today announced that a license agreement has been signed with the Spanish National Cancer Research Centre in Madrid in the area of cancer drug development. The global agreement will build upon CNIO research discoveries to encourage the development and commercialization of new compounds in the field of oncology.

18 Dec 2013

Elekta to launch MOSAIQ oncology information system throughout McLaren's cancer network

The ability to effectively manage data across disparate health systems to help drive quality care will be a cornerstone for health systems of the future. Elekta is proud to announce today that it has joined forces with Michigan-based McLaren Health Care to launch MOSAIQ oncology information system throughout McLaren's cancer network.

From Elekta 18 Dec 2013

Merck initiates clinical trial to evaluate MK-3475 and pazopanib in advanced renal cell carcinoma

Merck, known as MSD outside the United States and Canada, today announced the initiation of a clinical trial to evaluate the combination of the company's investigational anti-PD-1 immunotherapy, MK-3475, and GlaxoSmithKline's orally administered kinase inhibitor, pazopanib, in advanced renal cell carcinoma.

18 Dec 2013

Elekta and McLaren Health Care to launch MOSAIQ oncology information system

The ability to effectively manage data across disparate health systems to help drive quality care will be a cornerstone for health systems of the future. Elekta is proud to announce today that it has joined forces with Michigan-based McLaren Health Care to launch MOSAIQ® oncology information system throughout McLaren's cancer network.

From Elekta 18 Dec 2013

Research examines link between opioid suppression of immune system and cancer recurrence

The methods used to anesthetize prostate cancer patients and control pain when their prostate glands are surgically removed for adenocarcinoma may affect their long-term cancer outcomes, a study led by Mayo Clinic has found.

18 Dec 2013

Tumor News and Research

Experimental drug inhibits BTK molecule in patients with chronic lymphocytic leukemia

Joint initiative aims to eradicate health disparities among communities of color in the U.S.

Study finds milk serves as protective carrier of bioactive molecules

Researchers identify molecular link between liver cancer, obesity, alcoholism, and hepatitis

New research assesses nanomedicine-based approaches for treating cancer

Immunologists discover risk factor responsible for infectious mononucleosis in young people

Takeda to acquire exclusive license to develop Natrogen's Natura-alpha compound

BeiGene doses first patient in Phase 1 study of BGB-283

Researchers receive Doris Duke Foundation award to predict sickle cell crisis, monitor treatments

Blaze Bioscience to initiate first Phase 1 clinical study of BLZ-100 in patients with skin tumors

Abramson Cancer Center of the University of Pennsylvania celebrates 40th anniversary

LSDF announces research and development grants to commercialize health-related technologies

TGen, Nemucore, and Barrow collaboration aims for new drugs to treat glioblastoma

Researchers receive Special Challenge Award to investigate role of high protein levels in prostate tumors

Aerobic glycolysis is a cause of malignancy, show Berkeley Lab researchers

Merck signs license agreement with CNIO for cancer drug development

Elekta to launch MOSAIQ oncology information system throughout McLaren's cancer network

Merck initiates clinical trial to evaluate MK-3475 and pazopanib in advanced renal cell carcinoma

Elekta and McLaren Health Care to launch MOSAIQ oncology information system

Research examines link between opioid suppression of immune system and cancer recurrence

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News